OCT 22, 2020 3:05 PM CEST

NGS for precision oncology in solid tumors: from research to clinical practice

C.E. Credits: P.A.C.E. CE Florida CE
Speaker
  • Director of the Cell Biology and Biotherapy Unit and Translational Research Department, National Cancer Institute Fondazione G. Pascale, Naples
    Biography

      Dr. Normanno, MD earned his Medical Doctor Degree in 1988 at the Medical School, University of Naples (Italy) Federico II. After a residency in Oncology at the Oncology Department of the same university, in 1991 he achieved the specialisation in Medical Oncology, and in 2001 in Haematology. Between 1990 and 1993, Dr Normanno did a postdoctoral fellowship at the Tumor Growth Factor Section, Laboratory of Tumour Immunology and Biology, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. After being senior Investigator and later Acting Chief (2004-2005) at the Experimental Therapy Section, INT-Fondazione Pascale, Naples, Dr Normanno is currently Director of the Cell Biology and Biotherapy-Unit at the same Hospital, and since 2006 also Director of the Translational Research Department. Since 1993 Dr Normanno's area of research has been the study of the role of growth factors and receptors of the EGF family in the pathogenesis of solid tumors; the identification of markers of response or resistance to anti-EGFR agents; the implementation of precision medicine in the path of care of cancer patients. Dr Normanno is a member of the European Society for Medical Oncology (ESMO), the American Association for Cancer Research (AACR), the Italian Association of Medical Oncology (AIOM), and the Italian Cancer Society (SIC). He is from 2018 President of the International Quality Network for Pathology (IQN Path) and from 2020 President of the Italian Cancer Society (SIC). Dr Normanno is a reviewer for several peer-reviewed journals including Annals of Oncology, Clinical Cancer Research, International Journal of Cancer, European Journal of Cancer, British Journal of Cancer, Nature Communications. He is also Editor of Exploration of Targeted Anti-tumor Therapy and Associate Editor of BMC Cancer and Gene. Dr Normanno is the author of over 200 papers published in peer-reviewed journals with an H Index of 68.


    Abstract

    Precision oncology is revolutionizing the diagnostic and therapeutic approach to cancer. In fact, the availability of tumor-specific and tumor-agnostic biomarkers and matched therapies is rapidly increasing. For example, targets for therapeutic intervention have been found in over 50% lung adenocarcinoma and intra-hepatic cholangiocarcinoma. Therefore, diagnostic laboratories will face the problem to assess different types of genetic alterations (single nucleotide variants, indels, copy number variation and gene fusions) in multiple genes in order to allow the identification of the most active treatment for patients with metastatic cancer. Next generation sequencing (NGS) and in particular targeted sequencing allows sequencing dozen to hundred genes in a single analysis. The European Society of Medical Oncology (ESMO) recently released recommendations on the use of NGS for patients with metastatic solid tumors. According to ESMO recommendations, NGS is the preferred diagnostic approach to assess actionable genomic alterations ready for clinical practice in selected cancer types, including lung adenocarcinoma, prostate cancer and cholangiocarcinoma. However, the use of larger panels for comprehensive genomic profiling is suggested in academic centers. These recommendations for the first time provide a rationale for the use of NGS in the clinical practice. The increasing number of biomarkers and matched therapies that are being approved will likely lead to an extension of the recommendation to use NGS to other tumor types.

    Learning Objectives:
    1. To increase the knowledge on precision oncology for solid tumors.
    2. To increase the knowledge on the utility of next generation sequencing for genomic profiling of solid tumors.


    Show Resources
    You May Also Like
    SEP 10, 2020 9:00 AM PDT
    C.E. CREDITS
    SEP 10, 2020 9:00 AM PDT
    Date: September 10, 2020 Time: 9:00am (PDT), 12:00pm (EDT) Osmolality testing is relevant throughout the entire bioprocessing workflow. As customers look to refine mAb and gene therapy workf...
    SEP 03, 2020 9:00 AM PDT
    C.E. CREDITS
    SEP 03, 2020 9:00 AM PDT
    DATE: September 3, 2020 TIME: 09:00am PT, 12:00pm ET xxx Learning Objectives: xxx Webinars will be available for unlimited on-demand viewing after live event. LabRoots is approved as a provi...
    C.E. CREDITS
    This drug development program is designed to create a family of broad-spectrum, pan-coronaviral drugs that respectively inhibit multiple key enzymes required for viral replication. By target...
    JUN 17, 2020 1:30 PM PDT
    C.E. CREDITS
    JUN 17, 2020 1:30 PM PDT
    Understanding the complex interplay between a pathogen and the host response is important to developing effective vaccines and therapeutics. The nCounter® Analysis System and GeoMx®...
    NOV 05, 2020 7:00 AM PST
    C.E. CREDITS
    NOV 05, 2020 7:00 AM PST
    DATE: Date needed, 2020 TIME: Time needed Exosomes are a population of naturally occurring mobile, membrane-limited, 30 – 100 nm in diameter, extracellular vesicles containing a large...
    NOV 19, 2020 8:00 AM GMT
    C.E. CREDITS
    NOV 19, 2020 8:00 AM GMT
    Date: November 19, 2020 Time: 12:00am (PDT), 9:00am (CET), 4:00pm (SGT) We present split-FISH, a multiplexed fluorescence in situ hybridization method that leverages a split-probe design to...
    Loading Comments...
    Show Resources